HIV-1 Vaccine-Induced T-Cell Reponses Cluster in Epitope Hotspots that Differ from Those Induced in Natural Infection with HIV-1

PLoS Pathogens

Volumn 9, Issue 6, 2013, Pages

  Hertz, Tomer ^a   Ahmed, Hasan ^a   Friedrich, David P ^a   Casimiro, Danilo R ^b   Self, Steven G ^a   Corey, Lawrence ^a   McElrath, M Juliana ^a   Buchbinder, Susan ^c   Horton, Helen ^d   Frahm, Nicole ^a   Robertson, Michael N ^b   Graham, Barney S ^e   Gilbert, Peter ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^d SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ARTICLE; EPITOPE MAPPING; HLA TYPING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREDICTION; T LYMPHOCYTE;

AIDS VACCINES; COHORT STUDIES; EPITOPES, T-LYMPHOCYTE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE;

ADENOVIRIDAE; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84879515547     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003404     Document Type: Article

References (30)

1. McElrath MJ, Haynes BF, (2010) Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 33: 542-554.
2. Russell ND, Hudgens MG, Ha R, Havenar-Daughton C, McElrath MJ, (2003) Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity. The Journal of infectious diseases 187: 226-242.
3. Frahm N, Korber BT, Adams CM, Szinger JJ, Draenert R, et al. (2004) Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. Journal of Virology 78: 2187-2200.
4. Cao J, McNevin J, Holte S, Fink L, Corey L, et al. (2003) Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection. Journal of Virology 77: 6867-6878.
5. Streeck H, Jolin JS, Qi Y, Yassine-Diab B, Johnson RC, et al. (2009) Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells. Journal of Virology 83: 7641-7648.
6. Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, et al. (2011) International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 29: 5203-5209.
7. Barouch DH, Klasse PJ, Dufour J, Veazey RS, Moore JP, (2012) Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission. Proceedings of the National Academy of Sciences of the United States of America 109: 8694-8698.
8. Sheets RL, Stein J, Bailer RT, Koup RA, Andrews C, et al. (2008) Biodistribution and toxicological safety of adenovirus type 5 and type 35 vectored vaccines against human immunodeficiency virus-1 (HIV-1), Ebola, or Marburg are similar despite differing adenovirus serotype vector, manufacturer's construct, or gene inserts. Journal of immunotoxicology 5: 315-335.
9. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, et al. (2008) HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372: 1894-1905.
10. Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, et al. (2008) Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clinical Infectious Diseases 46: 1769-1781.
11. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881-1893.
12. Peiperl L, Morgan C, Moodie Z, Li H, Russell N, et al. (2010) Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054). PLoS ONE 5: e13579.
13. Hutnick NA, Carnathan DG, Dubey SA, Cox KS, Kierstead L, et al. (2009) Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells. Nature Medicine 15: 876-878.
14. O'brien KL, Liu J, King SL, Sun Y-H, Schmitz JE, et al. (2009) Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nature Medicine 15: 873-875.
15. Gilbert PB, Sato A, Sun X, Mehrotra DV, (2009) Efficient and robust method for comparing the immunogenicity of candidate vaccines in randomized clinical trials. Vaccine 27: 396-401.
16. Mothe B, Llano A, Ibarrondo J, Daniels M, Miranda C, et al. (2011) Definition of the viral targets of protective HIV-1-specific T cell responses. Journal of Translational Medicine 9: 208.
17. Mothe B, Llano A, Ibarrondo J, Zamarreno J, Schiaulini M, et al. (2012) CTL Responses of High Functional Avidity and Broad Variant Cross-Reactivity Are Associated with HIV Control. PLoS ONE 7: e29717.
18. Dinges WL, Richardt J, Friedrich D, Jalbert E, Liu Y, et al. (2010) Virus-specific CD8+ T-cell responses better define HIV disease progression than HLA genotype. Journal of Virology 84: 4461-4468.
19. Gilbert PB, Hudgens MG, (2008) Evaluating candidate principal surrogate endpoints. Biometrics 64: 1146-1154.
20. Follmann D, (2006) Augmented designs to assess immune response in vaccine trials. Biometrics 62: 1161-1169.
21. Altfeld M, Rosenberg ES, Shankarappa R, Mukherjee JS, Hecht FM, et al. (2001) Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. The Journal of experimental medicine 193: 169-180.
22. Addo MM, Yu XG, Rathod A, Cohen D, Eldridge RL, et al. (2003) Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. Journal of Virology 77: 2081-2092.
23. Hertz T, Nolan D, James I, John M, Gaudieri S, et al. (2011) Mapping the landscape of host-pathogen coevolution: HLA class I binding and its relationship with evolutionary conservation in human and viral proteins. Journal of Virology 85: 1310-1321.
24. Peters B, Bui H-H, Frankild S, Nielson M, Lundegaard C, et al. (2006) A community resource benchmarking predictions of peptide binding to MHC-I molecules. PLoS Computational Biology 2: e65.
25. Lin H, Ray S, Tongchusak S, Reinherz EL, Brusic V, (2008) Evaluation of MHC class I peptide binding prediction servers: Applications for vaccine research. BMC Immunology 9: 8.
26. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, et al. (2012) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. The New England journal of medicine 366: 1275-1286.
27. Li F, Finnefrock AC, Dubey SA, Korber BTM, Szinger J, et al. (2011) Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study. PLoS ONE 6: e20479.
28. Rolland M, Tovanabutra S, DeCamp AC, Frahm N, Gilbert PB, et al. (2011) Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nature Medicine 17: 366-371.
29. Hudgens MG, Self SG, Chiu Y-L, Russell ND, Horton H, et al. (2004) Statistical considerations for the design and analysis of the ELISpot assay in HIV-1 vaccine trials. Journal of immunological methods 288: 19-34.
30. Jojic N, Reyes-Gomez M, Heckerman D, Kadie C, Schueler-Furman O, (2006) Learning MHC I-peptide binding. Bioinformatics (Oxford, England) 22: e227-235.